Sinovac Biotech COVID-19 Vaccine Offers 51% Efficacy in Phase 3 Trials; Files Conditional Marketing Authorization in China
04:25 PM EST, 02/05/2021 (MT Newswires) -- China's Sinovac Biotech (SVA) said late Friday results from the Phase 3 trials of its COVID-19 vaccine demonstrated an efficacy rate of almost 51% for all cases.
The rate was 83.7% for cases requiring medical treatment, and 100% for hospitalized, severe, and fatal cases, according to a statement.
About 12,396 healthcare workers over 18 years old were enrolled in the trials as of Dec. 16. The efficacy rate was calculated 14 days after vaccination with two doses. The Phase 3 trials conducted in Brazil and Turkey evaluated the efficacy of the vaccine candidate in healthcare workers who provide treatment to COVID-19 patients.
Sinovac said it has filed a conditional market authorization for CoronaVac with China's National Medical Products Administration.
Price: 6.47, Change: 0.00, Percent Change: 0.00